• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    I-VASC Raises 1.8M Euros in Series A Funding

    Endotronix Shares Positive SIRONA 2 Heart Failure Trial Data

    FDA Clears Truvic's Prodigy Thrombectomy System

    Medical Device CEO Charged With Tax Evasion

    MPO's Most-Read Stories This Week—May 21
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Cirtec Medical

    Fusion Biotec Inc.

    Concise Engineering

    Xact Wire EDM Corp.

    Trademark Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Cirtec Medical

    Fusion Biotec Inc.

    Concise Engineering

    Xact Wire EDM Corp.

    Trademark Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    To Clinical or Not to Clinical, That Is the Question

    ...

    To Clinical or Not to Clinical, That Is the Question
    Related CONTENT
    • Robson Advisors
    • Driving Innovation and Improving Quality with 3D Printing
    • Quality Nightmares #38: Audit Selection
    • Software Validation: How It Should Be Done
    • FDA Authorizes First Test for Emerging Pathogen Candida Auris
    David C. Robson, Principal, Robson Advisors05.03.18
    For simple or well-characterized medical products, it is risk-appropriate and most cost effective to immediately design and engineer the commercial configuration of the device. In these cases, the design would presumably be sufficiently “locked in,” meaning the potential for substantial oversights is virtually nil. The OEM management team could therefore decide the product could be designed to go straight into commercial manufacturing, without any interim product configurations.

    But for more complex medical devices, the company should seriously consider developing a “clinical-grade” product configuration before spending the time and money refining the myriad facets of a “commercial-grade” design. This is especially true for devices that introduce novel clinical treatments or new-to-industry functionality, or those that have not yet settled on specific treatment parameters or functional tolerance ranges.

    Whereas a commercial-grade design should satisfy all the requirements for a product to be successful (e.g., safety, effectiveness, profit margin, etc.), a clinical-grade design primarily focuses on proving the clinical function is reliable. This focus allows the sponsoring company to postpone some secondary items for later. Generally, the design will include the key components that are intended as part of the commercial solution but the design will not have been fully streamlined.

    Below are some of the reasons developing a clinical-grade or interim product configuration can be beneficial. For each of these reasons, a proper balance is required to determine how much work can be wisely postponed. Also, any components and configurations should be close approximations to the eventual commercial solution.

    Less focus on cost of goods and profit margin objectives. It goes without saying that cost of goods and resulting profit margin are critical objectives for a commercially successful product. However, tuning a product design to hit a cost model is a big undertaking. It requires consideration of part count reduction, alternate component materials or fabrication methods, streamlining of manufacturing procedures, and so on. The clinical-grade design often aims to answer foundational questions concerning how the product functions or what clinical treatment ranges will be required—cost engineering can be left for later.

    Less focus on the device’s physical size. A clinical-grade design can often relax some of the size requirements, as long as the product’s size doesn’t negatively impact the effectiveness of the device. Like the postponement of cost of goods optimization, the miniaturization process should only be pursued once the foundational functions and clinical success of the product have been confirmed.

    Less focus on some aspects of functionality and human factors. Most products have primary or foundational functions. These are the elements that need to be fully embodied and confirmed in the clinical-grade approach. Secondary items and some of the refined human factors considerations can often be postponed unless there is uncertainty about their acceptability. For instance, a solution ultimately intended for handheld use may not be as lightweight or as easy to grasp in the clinical-grade design.

    Secondary software functions can be postponed. Many medical devices employ sophisticated sensing and analysis tools to determine something. These are the critical-to-success items that the clinical-grade solution should focus upon, whereas non-critical functions should be held for later. Likewise, figuring out exactly how the screens navigate to secondary screens—language selection, for example—is work that can wait for the commercial embodiment.

    Prototype materials may be sufficient. Since a clinical-grade product is an interim stage in the development cycle, it may be justified to use prototype materials. Although they may be more expensive on a per unit basis and are often less durable, these materials can be acquired much faster and often with no capital investment.

    The development team can construct units under reduced process controls. Getting a commercial-grade manufacturing line arranged is another large undertaking. The clinical-grade approach can allow the team to insert direct inspections into the assembly process that may not be acceptable in the longer term.

    Sterilization validation could be postponed or reduced. Depending upon the product and the intended use of the clinical-grade design, it may be possible to use simplified and smaller scale sterilization methods which would otherwise be prohibitively expensive for a commercial production solution.

    Less focus on some aspects of risk management and fool-proofing. For most clinical-grade evaluation efforts, testing is done under tighter and more controlled situations. Doctors and other users of the product can receive more training and oversight than would be possible for the eventual commercial release. This may allow for lower hazards analysis scoring, which in turn may simplify some of the safety features that need to be incorporated into the clinical-grade configuration.

    The design can be purposely engineered to allow adjustments. Employing a clinical-grade approach can allow the development team to include adjustable features or functions that may be inappropriate or unwanted in the commercial solution. This can be very helpful when trying to perfect an uncertain set of human-machine interfaces or user experiences. Similarly, the ability to test different component designs or materials or collect extra data can be accommodated in the clinical-grade solution, where such adjustability would be too costly or clunky for the commercial version.

    Results can support eventual regulatory submissions. There are limitations to what kind of data the FDA or the EU will accept from product testing not done on the final design. However, in some cases risk-appropriate rationales can be made that the clinical-grade solution is sufficiently similar and can be used to support eventual submissions.

    In some cases, the clinical-grade solution could be the first commercial offering. If the device offers a novel treatment or has a strong clinical advantage over competitive solutions, there will be early adopters who will want to use it—even if it’s a little clunkier or doesn’t have a fully refined feature set. While the clinical-grade solution will not be as cost-effective as the eventual commercial solution, it could be designed and submitted for regulatory approval such that it can be offered for sale. This then gives the developing company real-world information and feedback, which can be incorporated into the larger scale commercial solution.

    It’s important to remember that converting the clinical-grade design to the commercial-grade solution should be evolutionary, not revolutionary. Many management teams of old will balk at the idea of “developing the product twice.” They may see the clinical-grade solution as an unnecessary half measure. They want the development team to develop the right product first without any mistakes. However, for complex medical systems, going straight to the commercial design increases the risk of including an “Achilles heel” in the design or misaligning the cost-function-quality balance.

    An Achilles heel in terms of a product design is an issue or error that is fundamental to the product and cannot be “designed out.” An Achilles heel issue can permanently destroy a new product line and its revenue potential. It’s much better to discover these types of problems early in the development cycle, so the team can adjust the design or, if need be, kill the project.

    The commercial solution is ideally a “tailored” version of the clinical design. Parts can be refined for injection molding and other mass production processes. The secondary control screens and software control can be added. Final verification and validation testing can then be pursued.

    If done correctly, the clinical device will have answered all the hard questions and helped to determine the exact functional ranges and tolerances. Further, the clinical solution will reveal design and durability flaws that would have been discovered during the design verification testing of the commercial configuration.

    The overall project schedule of including development of a clinical-grade solution may have a longer timeline, but the risk profile will be better controlled. Anyone that has been developing medical devices for a while knows the suffering that occurs when a product experiences a drastic “excursion” from the project plan. It can drain the life out the project team and put companies out of business. 


    David C. Robson, a principal at Robson Advisors, has spent 30 years concentrating on the development of medical devices. Seventeen of those years were spent working for a full-service product development firm where he interacted with both large and small medical device companies and reviewed statements of work and requests for quotation, wrote proposals, and negotiated hundreds of work agreements. Robson and his partners now offer product development guidance and advocacy to early-stage medical device clients.
    Related Searches
    • risk management
    • hazards
    • validation
    • guidance
    Related Knowledge Center
    • R&D & Design
    Suggested For You
    Robson Advisors Robson Advisors
    Driving Innovation and Improving Quality with 3D Printing Driving Innovation and Improving Quality with 3D Printing
    Quality Nightmares #38: Audit Selection Quality Nightmares #38: Audit Selection
    Software Validation: How It Should Be Done Software Validation: How It Should Be Done
    FDA Authorizes First Test for Emerging Pathogen Candida Auris FDA Authorizes First Test for Emerging Pathogen Candida Auris
    FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach
    FDA Clears Cantel Medical FDA Clears Cantel Medical's Automated Endoscope Reprocessor
    FDA Clears Roche FDA Clears Roche's Chlamydia and Gonorrhea Molecular Tests
    FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests
    FDA FDA's Expansion of 510(k) Program Seeks to End Predicate Testing for Some Devices
    FDA Clears AI-Based Device to Detect Diabetic Retinopathy FDA Clears AI-Based Device to Detect Diabetic Retinopathy
    How Do I Serve Thee? Let Me Count the Ways How Do I Serve Thee? Let Me Count the Ways
    ‘Wait, What’s My Motivation?’ Keeping a Clear Eye on Priorities ‘Wait, What’s My Motivation?’ Keeping a Clear Eye on Priorities
    Absence Makes the Heart Grow Cold: Ensuring Regular Client/Service Provider Contact Absence Makes the Heart Grow Cold: Ensuring Regular Client/Service Provider Contact
    10 Steps to a Successful Product Development Arrangement 10 Steps to a Successful Product Development Arrangement

    Related Content

    • Robson Advisors

      ...
      David Robson, Principal 11.16.20

    • 3D/Additive Manufacturing
      Driving Innovation and Improving Quality with 3D Printing

      Driving Innovation and Improving Quality with 3D Printing

      With more than 100 FDA cleared 3D-printed devices, manufacturers should be investigating this technology.
      Eric M. Luyer, Market Research Analyst, Axendia Inc. 05.01.18

    • Software & IT
      Quality Nightmares #38: Audit Selection

      Quality Nightmares #38: Audit Selection

      Quality Nightmares offers a humorous look at the challenges faced by medtech professionals.
      MasterControl 04.27.18


    • Software & IT
      Software Validation: How It Should Be Done

      Software Validation: How It Should Be Done

      With vague guidance from FDA, device makers need to ensure they are using best practices.
      Erin Wright, Validation Product Manager, MasterControl 04.26.18

    • Diagnostics
      FDA Authorizes First Test for Emerging Pathogen Candida Auris

      FDA Authorizes First Test for Emerging Pathogen Candida Auris

      C. auris is a drug resistant yeast that can cause serious infections in hospitalized patients.
      U.S. Food and Drug Administration 04.23.18


      Breaking News
      • I-VASC Raises 1.8M Euros in Series A Funding
      • Endotronix Shares Positive SIRONA 2 Heart Failure Trial Data
      • FDA Clears Truvic's Prodigy Thrombectomy System
      • RSIP Vision Develops New AI Tool for Prostate MRI Analysis
      • Medical Device CEO Charged With Tax Evasion
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Vitafoods Europe 2022 Attendance Returns to 2019 Level
      Beyond Raw Launches Concept X Pre-Workout Line
      Botanical Ingredient MorActive Evidenced to Relieve Back Discomfort
      Coatings World

      Latest Breaking News From Coatings World

      PPG’s Diane Kappas Recognized as ‘Woman of Influence’ by Pittsburgh Business Times
      BEHR Launches COPPER FORCE Interior Paint
      A New Kind of Primer: Demand for Interior and Exterior Paint Experts Remains High, J.D. Power Finds
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      I-VASC Raises 1.8M Euros in Series A Funding
      Endotronix Shares Positive SIRONA 2 Heart Failure Trial Data
      FDA Clears Truvic's Prodigy Thrombectomy System
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Thermo Fisher, Qatar Genome Program Partner to Advance Precision Medicine
      CPC Launches AseptiQuik Genderless Connector
      Aptamer Group and PinotBio Extend Collaboration Agreement
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      L’Oréal USA Names Han Wen as Chief Digital & Marketing Officer
      NPD Group Reports on Rising E-commerce Sales in China for Prestige Beauty
      Noon Aesthetics Celebrates Ten Years with New Skincare Products
      Happi

      Latest Breaking News From Happi

      Gabriel Letizia Jr. Sentenced to 60 Months in Prison for Falsifying Sunscreen Test Results
      Coptis Appoints Marie Renee Thadal Vice President of Sales and Operations
      Han Wen Appointed L’Oréal’s New Chief Digital, Marketing Officer
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Avery Dennison announces Core Series Portfolio Tape Selector App
      HP Indigo reaches 2,000th active install milestone
      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Ahlstrom-Munksjö Announces Reorganization of Decor Business Ownership
      Jones Names COO
      Ontex Conducts Pilot Program of Digital Incontinence Care Solution
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Tom Hedman Named Senior Principal Scientist at Spinal Simplicity
      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login